|
1
|
|
Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, evaluated with and without tetanus-reduced diphtheria-acellular pertussis vaccine in healthy children aged 6-17 years: a randomised, active-controlled and placebo-controlled, phase 2b trial.
(linkinghub.elsevier.com)
|
Faust SN
…
Noviello S
Lancet Infectious Diseases
2026-10-01
|
#vaccination
#immunogenicity
#pertussis
#clinical trial
#mucosal-immunity
|
|
1
|
|
Emergence of Macrolide-Resistant Bordetella pertussis, Peru, 2025.
(wwwnc.cdc.gov)
|
Juscamayta-Lopez E
…
Da Costa AR
Emerging Infectious Diseases
2026-10-01
|
#pertussis
#amr
#sequencing
#surveillance
#outbreak
|
|
1
|
|
Age Differences in Pertussis Epidemics, New South Wales, Australia, 2015 and 2024.
(wwwnc.cdc.gov)
|
Madden EF
…
Amin J
Emerging Infectious Diseases
2026-10-01
|
#pertussis
#epidemiology
#immunity
#vaccination
|